2023-509688-25-00
招募中
1 期
Phase IB Study to Assess the Safety, Tolerability and Efficacy of PM14 in combination with Atezolizumab in Pretreated Patients with Selected Advanced Solid Tumors
概览
- 阶段
- 1 期
- 干预措施
- 未指定
- 疾病 / 适应症
- 未指定
- 发起方
- Pharma Mar S.A.
- 入组人数
- 50
- 试验地点
- 5
- 状态
- 招募中
- 最后更新
- 去年
概览
简要总结
暂无简介。
研究者
Clinical Development Oncology Unit
Scientific
Pharma Mar S.A.
入排标准
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
未指定
研究点 (5)
Loading locations...
相似试验
已完成
1 期
A phase Ib study to investigate the safety and effect of BR-0032024-516338-37-00SentryX B.V.6
招募中
1 期
A Phase IB Study to determine efficacy and safety of Durvalumab and/or novel anti-cancer agents, with or without chemotherapy, in patients with previously untreated NSCLC2024-511956-42-00AstraZeneca AB44
已完成
1 期
Assessing the safety and tolerability of oral ruxolitinib in combination with 5-azacitidine in patients with advanced phase myeloproliferative neoplasms (MPN), including myelodysplastic syndromes (MDS) or acute myeloid leukaemia (AML) arising from MPN.Myeloproliferative neoplasms (MPN), including myelodysplastic syndromes (MDS) or acute myeloid leukaemia (AML) arising from MPNCancerMalignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissueISRCTN16783472The University of Birmingham (UK)58
进行中（未招募）
不适用
Phase I study evaluating tolerability, safety, pharmacokinetics, and efficacy of combined ONO-4059 and R-MPV therapy for PCNSLjRCT2071230124Ono Pharmaceutical Co.,LTD20
招募中
不适用
Evaluate the Safety, Tolerability, Biodistribution Characteristics and Preliminary Efficacy of BioTTT001NCT07264569Henan Cancer Hospital42